{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T06:33:38Z","timestamp":1774506818406,"version":"3.50.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T00:00:00Z","timestamp":1586390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T00:00:00Z","timestamp":1586390400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006778","name":"Georgia Institute of Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006778","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000928","name":"Welch Foundation","doi-asserted-by":"publisher","award":["C-1565"],"award-info":[{"award-number":["C-1565"]}],"id":[{"id":"10.13039\/100000928","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000928","name":"Welch Foundation","doi-asserted-by":"publisher","award":["C-1565"],"award-info":[{"award-number":["C-1565"]}],"id":[{"id":"10.13039\/100000928","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["1R35GM-118039"],"award-info":[{"award-number":["1R35GM-118039"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["1R35GM-118039"],"award-info":[{"award-number":["1R35GM-118039"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["1R35GM-118039"],"award-info":[{"award-number":["1R35GM-118039"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences"},{"name":"U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences"},{"name":"The Andrew McDonough B+ Foundation (to J.S.) Welch Foundation grant C-1565 (to Y.J.T.)."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Diffuse intrinsic pontine glioma (DIPG) is a lethal pediatric brain cancer whose median survival time is under one year. The possible roles of the two most common DIPG associated cytoplasmic ACVR1 receptor kinase domain mutants, G328V and R206H, are reexamined in the context of new biochemical results regarding their intrinsic relative ATPase activities. At 37\u2009\u00b0C, the G328V mutant displays a 1.8-fold increase in intrinsic kinase activity over wild-type, whereas the R206H mutant shows similar activity. The higher G328V mutant intrinsic kinase activity is consistent with the statistically significant longer overall survival times of DIPG patients harboring ACVR1 G328V tumors. Based on the potential cross-talk between ACVR1 and T\u03b2RI pathways and known and predicted off-targets of ACVR1 inhibitors, we further validated the inhibition effects of several T\u03b2RI inhibitors on ACVR1 wild-type and G328V mutant patient tumor derived DIPG cell lines at 20\u201350\u2009\u00b5M doses. SU-DIPG-IV cells harboring the histone H3.1K27M and activating ACVR1 G328V mutations appeared to be less susceptible to T\u03b2RI inhibition than SF8628 cells harboring the H3.3K27M mutation and wild-type ACVR1. Thus, inhibition of hidden oncogenic signaling pathways in DIPG such as T\u03b2RI that are not limited to ACVR1 itself may provide alternative entry points for DIPG therapeutics.<\/jats:p>","DOI":"10.1038\/s41598-020-63061-0","type":"journal-article","created":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T10:03:56Z","timestamp":1586426636000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Differential kinase activity of ACVR1 G328V and R206H mutations with implications to possible T\u03b2RI cross-talk in diffuse intrinsic pontine glioma"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2496-1298","authenticated-orcid":false,"given":"Hongnan","family":"Cao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miao","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yizhi Jane","family":"Tao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Skolnick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,9]]},"reference":[{"key":"63061_CR1","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s11060-017-2372-5","volume":"132","author":"J Baugh","year":"2017","unstructured":"Baugh, J. et al. The international diffuse intrinsic pontine glioma registry: an infrastructure to accelerate collaborative research for an orphan disease. J Neurooncol 132, 323\u2013331 (2017).","journal-title":"J Neurooncol"},{"key":"63061_CR2","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s42003-019-0420-8","volume":"2","author":"D Carvalho","year":"2019","unstructured":"Carvalho, D. et al. ALK2 inhibitors display beneficial effects in preclinical models of ACVR1 mutant diffuse intrinsic pontine glioma. Commun Biol 2, 156 (2019).","journal-title":"Commun Biol"},{"key":"63061_CR3","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.ccell.2017.08.017","volume":"32","author":"A Mackay","year":"2017","unstructured":"Mackay, A. et al. Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma. Cancer Cell 32, 520\u2013537 e525 (2017).","journal-title":"Cancer Cell"},{"key":"63061_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11185","volume":"7","author":"H Nikbakht","year":"2016","unstructured":"Nikbakht, H. et al. Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma. Nat Commun 7, 11185 (2016).","journal-title":"Nat Commun"},{"key":"63061_CR5","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/ng.1102","volume":"44","author":"G Wu","year":"2012","unstructured":"Wu, G. et al. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet 44, 251\u2013253 (2012).","journal-title":"Nat Genet"},{"key":"63061_CR6","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/nm.4296","volume":"23","author":"A Piunti","year":"2017","unstructured":"Piunti, A. et al. Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas. Nat Med 23, 493\u2013500 (2017).","journal-title":"Nat Med"},{"key":"63061_CR7","doi-asserted-by":"publisher","first-page":"4453","DOI":"10.1073\/pnas.1101657108","volume":"108","author":"M Monje","year":"2011","unstructured":"Monje, M. et al. Hedgehog-responsive candidate cell of origin for diffuse intrinsic pontine glioma. Proc Natl Acad Sci USA 108, 4453\u20134458 (2011).","journal-title":"Proc Natl Acad Sci USA"},{"key":"63061_CR8","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.ccell.2017.03.011","volume":"31","author":"S Nagaraja","year":"2017","unstructured":"Nagaraja, S. et al. Transcriptional Dependencies in Diffuse Intrinsic Pontine Glioma. Cancer Cell 31, 635\u2013652 e636 (2017).","journal-title":"Cancer Cell"},{"key":"63061_CR9","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1126\/science.1253799","volume":"346","author":"K Funato","year":"2014","unstructured":"Funato, K., Major, T., Lewis, P. W., Allis, C. D. & Tabar, V. Use of human embryonic stem cells to model pediatric gliomas with H3.3K27M histone mutation. Science 346, 1529\u20131533 (2014).","journal-title":"Science"},{"key":"63061_CR10","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1038\/nm0715-827a","volume":"21","author":"CS Grasso","year":"2015","unstructured":"Grasso, C. S. et al. Functionally defined therapeutic targets in diffuse intrinsic pontine glioma. Nat Med 21, 827 (2015).","journal-title":"Nat Med"},{"key":"63061_CR11","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1038\/nm.3716","volume":"20","author":"R Hashizume","year":"2014","unstructured":"Hashizume, R. et al. Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma. Nat Med 20, 1394\u20131396 (2014).","journal-title":"Nat Med"},{"key":"63061_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-08823-9","volume":"10","author":"CM Hoeman","year":"2019","unstructured":"Hoeman, C. M. et al. ACVR1 R206H cooperates with H3.1K27M in promoting diffuse intrinsic pontine glioma pathogenesis. Nat Commun 10, 1023 (2019).","journal-title":"Nat Commun"},{"key":"63061_CR13","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1002\/ijc.32258","volume":"145","author":"S Mueller","year":"2019","unstructured":"Mueller, S. et al. A pilot precision medicine trial for children with diffuse intrinsic pontine glioma-PNOC003: A report from the Pacific Pediatric Neuro-Oncology Consortium. Int J Cancer 145, 1889\u20131901 (2019).","journal-title":"Int J Cancer"},{"key":"63061_CR14","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/ng.2936","volume":"46","author":"P Buczkowicz","year":"2014","unstructured":"Buczkowicz, P. et al. Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nat Genet 46, 451\u2013456 (2014).","journal-title":"Nat Genet"},{"key":"63061_CR15","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/ng.2925","volume":"46","author":"KR Taylor","year":"2014","unstructured":"Taylor, K. R. et al. Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma. Nat Genet 46, 457\u2013461 (2014).","journal-title":"Nat Genet"},{"key":"63061_CR16","doi-asserted-by":"publisher","first-page":"a022111","DOI":"10.1101\/cshperspect.a022111","volume":"8","author":"A Chaikuad","year":"2016","unstructured":"Chaikuad, A. & Bullock, A. N. Structural Basis of Intracellular TGF-beta Signaling: Receptors and Smads. Cold Spring Harb Perspect Biol 8, a022111 (2016).","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"63061_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF00928361","volume":"140","author":"TW Traut","year":"1994","unstructured":"Traut, T. W. Physiological concentrations of purines and pyrimidines. Mol Cell Biochem 140, 1\u201322 (1994).","journal-title":"Mol Cell Biochem"},{"key":"63061_CR18","doi-asserted-by":"publisher","first-page":"7900","DOI":"10.1021\/jm501177w","volume":"57","author":"AH Mohedas","year":"2014","unstructured":"Mohedas, A. H. et al. Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants. J Med Chem 57, 7900\u20137915 (2014).","journal-title":"J Med Chem"},{"key":"63061_CR19","doi-asserted-by":"publisher","first-page":"e62721","DOI":"10.1371\/journal.pone.0062721","volume":"8","author":"CE Sanvitale","year":"2013","unstructured":"Sanvitale, C. E. et al. A new class of small molecule inhibitor of BMP signaling. Plos One 8, e62721 (2013).","journal-title":"Plos One"},{"key":"63061_CR20","doi-asserted-by":"publisher","first-page":"36990","DOI":"10.1074\/jbc.M112.365932","volume":"287","author":"A Chaikuad","year":"2012","unstructured":"Chaikuad, A. et al. Structure of the bone morphogenetic protein receptor ALK2 and implications for fibrodysplasia ossificans progressiva. J Biol Chem 287, 36990\u201336998 (2012).","journal-title":"J Biol Chem"},{"key":"63061_CR21","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1159\/000324230","volume":"194","author":"JC Groppe","year":"2011","unstructured":"Groppe, J. C., Wu, J., Shore, E. M. & Kaplan, F. S. In vitro analyses of the dysregulated R206H ALK2 kinase-FKBP12 interaction associated with heterotopic ossification in FOP. Cells Tissues Organs 194, 291\u2013295 (2011).","journal-title":"Cells Tissues Organs"},{"key":"63061_CR22","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S0092-8674(00)80555-3","volume":"96","author":"M Huse","year":"1999","unstructured":"Huse, M., Chen, Y. G., Massague, J. & Kuriyan, J. Crystal structure of the cytoplasmic domain of the type I TGF beta receptor in complex with FKBP12. Cell 96, 425\u2013436 (1999).","journal-title":"Cell"},{"key":"63061_CR23","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1097-2765(01)00332-X","volume":"8","author":"M Huse","year":"2001","unstructured":"Huse, M. et al. The TGF beta receptor activation process: an inhibitor- to substrate-binding switch. Mol Cell 8, 671\u2013682 (2001).","journal-title":"Mol Cell"},{"key":"63061_CR24","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/370341a0","volume":"370","author":"JL Wrana","year":"1994","unstructured":"Wrana, J. L., Attisano, L., Wieser, R., Ventura, F. & Massague, J. Mechanism of activation of the TGF-beta receptor. Nature 370, 341\u2013347 (1994).","journal-title":"Nature"},{"key":"63061_CR25","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.bone.2018.03.015","volume":"111","author":"A Machiya","year":"2018","unstructured":"Machiya, A. et al. Effects of FKBP12 and type II BMP receptors on signal transduction by ALK2 activating mutations associated with genetic disorders. Bone 111, 101\u2013108 (2018).","journal-title":"Bone"},{"key":"63061_CR26","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1248\/cpb.c18-00598","volume":"67","author":"K Sekimata","year":"2019","unstructured":"Sekimata, K. et al. Bis-Heteroaryl Pyrazoles: Identification of Orally Bioavailable Inhibitors of Activin Receptor-Like Kinase-2 (R206H). Chem Pharm Bull (Tokyo) 67, 224\u2013235 (2019).","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"63061_CR27","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1021\/cb300655w","volume":"8","author":"AH Mohedas","year":"2013","unstructured":"Mohedas, A. H. et al. Development of an ALK2-biased BMP type I receptor kinase inhibitor. ACS Chem Biol 8, 1291\u20131302 (2013).","journal-title":"ACS Chem Biol"},{"key":"63061_CR28","doi-asserted-by":"publisher","first-page":"1260419","DOI":"10.1126\/science.1260419","volume":"347","author":"M Uhlen","year":"2015","unstructured":"Uhlen, M. Tissue-based map of the human proteome. Science 347, 1260419 (2015).","journal-title":"Science"},{"key":"63061_CR29","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1021\/acs.jcim.8b00309","volume":"58","author":"H Zhou","year":"2018","unstructured":"Zhou, H., Cao, H. & Skolnick, J. FINDSITE(comb2.0): A New Approach for Virtual Ligand Screening of Proteins and Virtual Target Screening of Biomolecules. J Chem Inf Model 58, 2343\u20132354 (2018).","journal-title":"J Chem Inf Model"},{"key":"63061_CR30","doi-asserted-by":"publisher","first-page":"aaw8412","DOI":"10.1126\/scitranslmed.aaw8412","volume":"11","author":"A Lin","year":"2019","unstructured":"Lin, A. et al. Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials. Sci Transl Med 11, aaw8412 (2019).","journal-title":"Sci Transl Med"},{"key":"63061_CR31","doi-asserted-by":"publisher","first-page":"eaav5183","DOI":"10.1126\/scisignal.aav5183","volume":"12","author":"R Derynck","year":"2019","unstructured":"Derynck, R. & Budi, E. H. Specificity, versatility, and control of TGF-beta family signaling. Sci Signal 12, eaav5183 (2019).","journal-title":"Sci Signal"},{"key":"63061_CR32","first-page":"215","volume":"134","author":"J Massague","year":"2008","unstructured":"Massague, J. TGFbeta in. Cancer. Cell 134, 215\u2013230 (2008).","journal-title":"Cancer. Cell"},{"key":"63061_CR33","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41580-018-0080-4","volume":"20","author":"A Dongre","year":"2019","unstructured":"Dongre, A. & Weinberg, R. A. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol 20, 69\u201384 (2019).","journal-title":"Nat Rev Mol Cell Biol"},{"key":"63061_CR34","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/nature10523","volume":"478","author":"HJ Kang","year":"2011","unstructured":"Kang, H. J. et al. Spatio-temporal transcriptome of the human brain. Nature 478, 483\u2013489 (2011).","journal-title":"Nature"},{"key":"63061_CR35","doi-asserted-by":"publisher","first-page":"4490","DOI":"10.1038\/sj.emboj.7601332","volume":"25","author":"S Ross","year":"2006","unstructured":"Ross, S. et al. Smads orchestrate specific histone modifications and chromatin remodeling to activate transcription. EMBO J 25, 4490\u20134502 (2006).","journal-title":"EMBO J"},{"key":"63061_CR36","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.trecan.2019.01.003","volume":"5","author":"JF Sarthy","year":"2019","unstructured":"Sarthy, J. F., Henikoff, S. & Ahmad, K. Chromatin Bottlenecks in Cancer. Trends Cancer 5, 183\u2013194 (2019).","journal-title":"Trends Cancer"},{"key":"63061_CR37","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/nature14221","volume":"518","author":"P Polak","year":"2015","unstructured":"Polak, P. et al. Cell-of-origin chromatin organization shapes the mutational landscape of cancer. Nature 518, 360\u2013364 (2015).","journal-title":"Nature"},{"key":"63061_CR38","doi-asserted-by":"publisher","first-page":"5421","DOI":"10.1046\/j.1432-1327.2000.01606.x","volume":"267","author":"J O\u2019Brien","year":"2000","unstructured":"O\u2019Brien, J., Wilson, I., Orton, T. & Pognan, F. Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur J Biochem 267, 5421\u20135426 (2000).","journal-title":"Eur J Biochem"},{"key":"63061_CR39","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.immuni.2019.03.024","volume":"50","author":"E Batlle","year":"2019","unstructured":"Batlle, E. & Massague, J. Transforming Growth Factor-beta Signaling in Immunity and Cancer. Immunity 50, 924\u2013940 (2019).","journal-title":"Immunity"},{"key":"63061_CR40","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1124\/jpet.104.082099","volume":"313","author":"ET Grygielko","year":"2005","unstructured":"Grygielko, E. T. et al. Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-beta type I receptor kinase in puromycin-induced nephritis. J Pharmacol Exp Ther 313, 943\u2013951 (2005).","journal-title":"J Pharmacol Exp Ther"},{"key":"63061_CR41","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1016\/j.bmcl.2009.02.087","volume":"19","author":"F Gellibert","year":"2009","unstructured":"Gellibert, F. et al. Design of novel quinazoline derivatives and related analogues as potent and selective ALK5 inhibitors. Bioorg Med Chem Lett 19, 2277\u20132281 (2009).","journal-title":"Bioorg Med Chem Lett"},{"key":"63061_CR42","first-page":"eaaw006","volume":"11","author":"GL Lin","year":"2019","unstructured":"Lin, G. L. et al. Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening. Sci Transl Med 11, eaaw006 (2019).","journal-title":"Sci Transl Med"},{"key":"63061_CR43","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ab.2004.04.031","volume":"332","author":"MC Lo","year":"2004","unstructured":"Lo, M. C. et al. Evaluation of fluorescence-based thermal shift assays for hit identification in drug discovery. Anal Biochem 332, 153\u2013159 (2004).","journal-title":"Anal Biochem"},{"key":"63061_CR44","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1758-2946-6-16","volume":"6","author":"B Srinivasan","year":"2014","unstructured":"Srinivasan, B., Zhou, H., Kubanek, J. & Skolnick, J. Experimental validation of FINDSITE(comb) virtual ligand screening results for eight proteins yields novel nanomolar and micromolar binders. J Cheminform 6, 16 (2014).","journal-title":"J Cheminform"},{"key":"63061_CR45","doi-asserted-by":"publisher","first-page":"e0150965","DOI":"10.1371\/journal.pone.0150965","volume":"11","author":"H Zhou","year":"2016","unstructured":"Zhou, H., Gao, M. & Skolnick, J. ENTPRISE: An Algorithm for Predicting Human Disease-Associated Amino Acid Substitutions from Sequence Entropy and Predicted Protein Structures. Plos One 11, e0150965 (2016).","journal-title":"Plos One"},{"key":"63061_CR46","doi-asserted-by":"publisher","first-page":"e0196849","DOI":"10.1371\/journal.pone.0196849","volume":"13","author":"H Zhou","year":"2018","unstructured":"Zhou, H., Gao, M. & Skolnick, J. ENTPRISE-X: Predicting disease-associated frameshift and nonsense mutations. Plos One 13, e0196849 (2018).","journal-title":"Plos One"},{"key":"63061_CR47","doi-asserted-by":"publisher","first-page":"2831","DOI":"10.1093\/bioinformatics\/btw358","volume":"32","author":"H Zhou","year":"2016","unstructured":"Zhou, H. & Skolnick, J. A knowledge-based approach for predicting gene-disease associations. Bioinformatics 32, 2831\u20132838 (2016).","journal-title":"Bioinformatics"},{"key":"63061_CR48","doi-asserted-by":"publisher","first-page":"6889","DOI":"10.1128\/MCB.01192-08","volume":"28","author":"AC Daly","year":"2008","unstructured":"Daly, A. C., Randall, R. A. & Hill, C. S. Transforming growth factor beta-induced Smad1\/5 phosphorylation in epithelial cells is mediated by novel receptor complexes and is essential for anchorage-independent growth. Mol Cell Biol 28, 6889\u20136902 (2008).","journal-title":"Mol Cell Biol"},{"key":"63061_CR49","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S1097-2765(03)00386-1","volume":"12","author":"MJ Goumans","year":"2003","unstructured":"Goumans, M. J. et al. Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFbeta\/ALK5 signaling. Mol Cell 12, 817\u2013828 (2003).","journal-title":"Mol Cell"},{"key":"63061_CR50","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.1128\/MCB.00231-12","volume":"32","author":"E Gronroos","year":"2012","unstructured":"Gronroos, E. et al. Transforming growth factor beta inhibits bone morphogenetic protein-induced transcription through novel phosphorylated Smad1\/5-Smad3 complexes. Mol Cell Biol 32, 2904\u20132916 (2012).","journal-title":"Mol Cell Biol"},{"key":"63061_CR51","doi-asserted-by":"crossref","first-page":"4467","DOI":"10.1242\/dev.124.22.4467","volume":"124","author":"AF Candia","year":"1997","unstructured":"Candia, A. F. et al. Cellular interpretation of multiple TGF-beta signals: intracellular antagonism between activin\/BVg1 and BMP-2\/4 signaling mediated by Smads. Development 124, 4467\u20134480 (1997).","journal-title":"Development"},{"key":"63061_CR52","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/nature11262","volume":"488","author":"L Kruidenier","year":"2012","unstructured":"Kruidenier, L. et al. A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. Nature 488, 404\u2013408 (2012).","journal-title":"Nature"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-63061-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-63061-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-63061-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T18:54:48Z","timestamp":1696013688000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-63061-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,9]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["63061"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-63061-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,9]]},"assertion":[{"value":"29 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6140"}}